Breast MRI for Surveillance - Cohort 2: Jan-Dec 2015
The American Society of Clinical Oncology, the American Cancer Society, and the American Society of Breast Surgeons recommends against performing a breast magnetic resonance imaging (MRI) for routine breast cancer surveillance for recurrence in asymptomatic patients who have been treated with curative intent, citing their unproven effectiveness in improving survival. Breast MRI is currently recommended only for women at very high risk for developing another breast cancer, such as BRCA1/2 mutation carriers, history of chest wall radiation therapy and women with a 20% or greater lifetime risk of developing another breast cancer. Breast MRI may be considered in women with very dense breasts or a strong family history of breast cancer. Breast MRI may also be indicated for follow-up of a prior abnormal breast MRI finding.
The results below represent the percentage of women with newly diagnosed breast cancer between 1/1/2015 to 06/30/2015 who received breast MRI later than 6 months from their definitive breast surgery date. These results are consistently calculated based on strict inclusion and measurement criteria applied to each institution's billing data. The exceptions noted above are not reflected in these criteria since they cannot be determined through billing data. The chance that results are biased is minimized since patients of different health systems are unlikely to differ systematically in the likelihood of these exceptions.
Note: Results presented here are part of a federal grant from the National Cancer Institute (NCI) awarded to investigators at the Medical College of Wisconsin. The organizations participating in this project agreed to do so on a voluntary basis, and represent a majority of the WCHQ membership eligible for the study.